The global transdermal drug delivery market study features a detailed analysis of systems and methods used for administering drugs to patients via the transdermal route. The analytical discussions, recommendations, and graphics offer you a holistic perspective of the demand-supply dynamics, market trends, growth opportunities, and barriers to growth in the global transdermal drug delivery market. This report drills deep into the many segments and sub-segments in this market. This allows users to gain a granular insight at both macro and micro levels.
Forecasts and estimates are provided for all key product segments within the transdermal drug delivery market up to 2017. These include: local pain patches, testosterone, nitroglycerin, tulobuterol, fentanyl, nicotine, estradiol, scopolamine, estadiol, and clonidine-based products for transdermal drug delivery. The report describes needleless and microneedle technologies used in this market.
Since this market is heavily influenced by technological innovation, the report also studies market forecasts and estimates for all key segments in transdermal drug delivery technology such as (both active and passive). Furthermore, the report segments the global transdermal drug delivery market based on geography, and studies each of these regional markets in detail.
A full review of global growth drivers and inhibitors is carried out as part of the scope of this study. Our analysts employ Porter’s five forces analysis model to determine the future competitiveness in the transdermal drug delivery market. They also assess threat from substitute drug delivery systems, and establish the future bargaining power of buyers and suppliers. The Company Profiles section of the report adds value to this market research report by offering an overview of the operations of all major market participants.
Overview of the transdermal drug delivery market
Transdermal drug delivery is a relatively new approach for delivering drugs to a patient. This approach administers drugs through the patient’s skin. The medicines or drugs that need to be administered to a patient are typically applied in the form of a patch, plaster or ointment so that the drugs can be slowly absorbed into the circulatory system.
This is fast becoming the preferred method of drug delivery because it offers several benefits and comforts over oral and invasive methods. Though oral drug delivery has been the most common over the recent past, it has numerous limitations which include drug degradation (resulting from enzymes and pH present in the gastrointestinal tract) or first pass metabolism.
Systems that are used for delivering drugs via the transdermal route are generally comprised of five key components: the drug itself, permeation enhancers, polymer matrix, adhesives, and finally, backing layers. Given that this drug delivery method uses the skin as a permeation route, it can be affected by the dermal condition of the patient. Transdermal drug delivery also depends on certain physiological and biological conditions of the patient in question.
Biological factors that directly affect the quality and efficacy of transdermal drug delivery are: the ‘age’ of the skin, skin condition, blood flow, skin metabolism, and local skin sites. Furthermore, this drug delivery method is also directly influenced by physiological factors including but not limited to: hydration levels of the skin, drug concentration, diffusion co-efficient, molecular size and shape, skin temperature, and pH levels.
In recent years, this market has been impelled by the introduction of easy-to-use and effective transdermal drug delivery systems based on cutting-edge technology. A case in point would be Nupathe Inc’s migraine treatment transdermal patches. This market has also grown because of a proportional demand for transdermal drug delivery systems which are decidedly more convenient than conventional systems for delivering drugs. For examples, patients that are intolerant to oral drug dosages, or those in a nauseated or unconscious state can be delivered drugs via the transdermal route. Transdermal patches offer better moderation and control over toxicity levels as these patches can simply be peeled off if the drug is observed to be rendering toxic effects. Drug permeation (and its effects) can be measured and monitored more effectively via this method, which makes it easier to maintain a consistent level of drug serum. In view of these factors, the adoption rate of products and systems in the global transdermal drug delivery market is higher.
By application, the global transdermal drug delivery market can be segmented as: pain management, contraception, hormone replacement therapy, neurological disorders, and smoking cessation.
Companies mentioned in the global transdermal drug delivery market report
This market research report features participants such as: Bayer AG, Novartis AG, 3M Pharmaceuticals Co., Mylan Laboratories Inc., Johnson & Johnson, Actavis Inc., and BioGel Technology Inc.
Geographies analyzed under this research report:
- North America
- Rest of the World
This report gives you access to decisive data such as:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years
Key highlights of this report:
- Overview of key market forces propelling and restraining market growth
- Up-to-date analyses of market trends and technological improvements in the micro servers industry
- Pin-point analyses of market competition dynamics to offer you a competitive edge
- An analysis of strategies of major competitors
- An array of graphics and SWOT analysis of major industry segments
- Detailed analyses of industry trends
- A well-defined technological growth map with an impact-analysis
- Offers a clear understanding of the competitive landscape and key product segments
Table of Contents
1.1. KEY TAKEAWAYS
1.2. REPORT DESCRIPTION
1.3. RESEARCH METHODOLOGY
1.5. KEY DEFINITIONS
1.6. FORECAST ASSUMPTIONS
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
3.1. MARKET DYNAMICS
3.2. IMPACT ANALYSIS OF DRIVERS
3.3. IMPACT ANALYSIS OF RESTRAINTS
3.4. SHIFTING DEMOGRAPHIC TRENDS
3.5. TRANSDERMAL TECHNOLOGY OVERVIEW
3.6. ADVANTAGES OF TRANSDERMAL DRUG DELIVERY SYSTEMS
3.7. FDA REGULATIONS
3.8. CLINICAL TRIAL PROCESS
3.9. KEY ISSUES FACED
3.10. THERAPEUTIC FOCUS
3.11. GEOGRAPHIC ANALYSIS OF SALES
3.12. LEADING PLAYERS
3.13. VALUE CHAIN ANALYSIS
3.14. MARKET SHARE ANALYSIS
3.15. FIVE FORCE ANALYSIS
3.15.1. BARGAINING POWER OF SUPPLIERS
3.15.2. BARGAINING POWER OF BUYERS
3.15.3. THREAT OF SUBSTITUTES
3.15.4. THREAT FROM NEW ENTRANTS
3.15.5. INTENSE OF COMPETITIVE RIVALRY
4. MARKET ANALYSIS
4.1. MARKET SIZE AND GROWTH
4.1.1. TRANSDERMAL DRUG DELIVERY MARKET
4.1.2. TRANSDERMAL DRUG DELIVERY MARKET BY GEOGRAPHY
188.8.131.52.1. MARKET OVERVIEW AND TRENDS
184.108.40.206.1. MARKET OVERVIEW AND TRENDS
220.127.116.11.1. MARKET OVERVIEW AND TRENDS
18.104.22.168.1. MARKET OVERVIEW AND TRENDS
4.2. TRANSDERMAL TECHNOLOGIES
4.2.1. ELECTRIC CURRENT
4.2.4. MECHANICAL ARRAYS
4.2.5. RADIO FREQUENCY
4.3. PRODUCT ANALYSIS
4.3.1. PAIN MANAGEMENT
4.3.6. PIPELINE OVERVIEW
6. COMPETITIVE LANDSCAPE
6.1. KEY MERGERS AND ACQUISITIONS
6.2. TECHNOLOGICAL INNOVATIONS IN TRANSDERMAL DRUG DELIVERY
7. COMPANY PROFILES
7.2. JOHNSON & JOHNSON
7.5. SKYEPHARMA PLC
7.6. TRANSDERMAL TECHNOLOGIES, INC.
7.7. BIOGEL TECHNOLOGY, INC.
7.8. BOEHRINGER INGELHEIM